Today´s health care industry depends greatly on complex research and innovation on pharmaceutical, genetics, biotechnology and medical devices sectors. A deeper knowledge in pathophysiology and the epidemiologic transition have driven this change, creating as well greater market opportunities. In Mexico, this service represents 5.5% of GDP and generates about 4% of employment in Mexico (INEGI).
Mexico has the second largest pharmaceutical market in Latin America, and it is also one of the worlds´s main manufacturing centers with presence of 20 multinational pharmaceutical companies. In 2013 the sector was valued at 13.98 billion USD. Meanwhile for that same year the exports of medical devices reached 6.89 billion USD. Mexico is the main supplier to the U.S. market.
It is expected that by 2025 the customer engagement within the health sector will be through electronic media in relation to laboratory tests, medications, and medical consultations.
